In detail, CD19+ CXCR3+ expressing B cells comprised 53.3 ± 2.9% (mean ± SEM) in RA and 47.1 ± 3.7 % in HD (p = 0.190), whereas the CD19+CXCR4+ B cells were 66.3 ± 2.5% in RA and 61.3 ± 3.4% in HD (p = 0.24). This evidence concerns the gene CXCR4 and rheumatoid arthritis.